Updated: Reimbursement Questions Jeopardize Hillrom/Bardy Merger
Executive Summary
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
You may also be interested in...
Baxter Plans To ‘Transform Health Care’ By Acquiring Hillrom For $12.4Bn
Baxter’s management justified the deal by emphasizing the potential cost synergies and shared commitment to digital health innovation.
Reports: Baxter May Acquire Hillrom For $10Bn
Media reports indicate Baxter is negotiating to acquire Hillrom for about $10bn, but the companies are not commenting on the reports.
iRhythm Is ‘Encouraged’ By Recent Reimbursement Discussions With Novitas
The company provided another update on its ongoing efforts to secure adequate Medicare reimbursement for long-term continuous cardiac monitoring.